Non-small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a frequently diagnosed cancer type and a leading cause of cancer-related death.¹

Treatments for NSCLC include surgery, chemotherapy, radiation therapy, and targeted therapy.² The treatment landscape of resectable NSCLC has been enhanced for patients with NSCLC following the approval of systemic treatments, such as atezolizumab, osimertinib, pembrolizumab, and nivolumab combined with chemotherapy.^3,4

Many clinical challenges persist in the face of these advances. For example, factors such as abnormal antigen presentation, functional gene mutation, and the tumour microenvironment can contribute to treatment resistance. The mechanisms of acquired resistance to these therapies are under investigation.³

Industry-sponsored resources

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
2. NCI, 2024. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. Accessed May 20, 2024.
3. Houda I, Dickhoff C, Uyl-De Groot CA, Damhuis RAM, Reguart N, Provencio M, et al. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. The Lancet. 2024;38:100841.
4. Houda I, Dickhoff C, Uyl-De Groot CA, Reguart N, Provencio M, Levy A, et al. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet. 2024;38:100840.